Drug developer Amarin Corp (AMRN.O) will retain a financial adviser to review its alternatives, Bloomberg reported. The company has been approached by more than a dozen interested parties, potential partners and buyers, Chief Executive Joe Zakrzewski said in an interview to the news agency. "I have more companies interested in this asset than employees," he told Bloomberg at the J.P. Morgan Healthcare Conference in San Francisco. The company employs 17 people, he added.
Source
